The ABPI's latest implementation report says 15,426 additional patients a year could be offered medicines because NICE raised its cost-effectiveness threshold. The figure is real but soft: it comes from company estimates of eligible patients across 10 appraisals. For market access teams the useful question is what sits behind it, and what it does not yet show.

What changed in the threshold

The government announced on 1 December 2025 that NICE would move from £20,000–£30,000 to £25,000–£35,000 per QALY. NICE said it already recommended 91% of the medicines it evaluates, around 70 a year, and that its own analysis suggested the change would allow an additional 3–5 new medicines or indications a year.

Two transition rules shape any early data. The new range applies to appraisals already underway. And where a committee judged a treatment not cost effective at the old range, and the new range might change that, NICE paused the topic until it had the power to apply the new thresholds.

What the CONNIE report counts

CONNIE is the ABPI's Continuous NICE Implementation Evaluation, built on company feedback about completed appraisals. Of 20 appraisals with final guidance between 1 April and 5 August 2026, the ABPI reports that half (10) had a better outcome for patients:

  • Nine of the 10 might not have been recommended. Companies said NICE may not have recommended them at the previous threshold.
  • Six could not have launched. Companies said they could not have launched in the UK under the previous threshold.
  • Seven were cancer medicines. The rest were two cardiovascular and one endocrine.

The ABPI sets this against government data showing nine additional medicines approved in England and Wales because of the change, eight of which appear in CONNIE. The ABPI states its own caveats plainly: the findings are company-reported, patient numbers are estimates of eligibility rather than patients treated, and the period included the pause on borderline appraisals.

A second data point

A separate ISPOR Europe 2026 poster from Precision AQ looked at public single technology appraisal outcomes. Recommendation rates were 23.3% between the December 2025 announcement and implementation, then 42.3% in the following three months, against 33.0% in 2025 and 36.2% across 2023–2025. Appraisals terminated because the manufacturer did not submit fell from 24.2% in 2025 to 19.2%, the first fall in three years.

The dip before implementation fits manufacturers holding back submissions until the higher range applied. The authors also warn that samples are small, and they suggest the higher willingness to pay may have eased manufacturers' concerns about Most Favoured Nation pricing. That second point is an interpretation, not a finding.

Who bears the cost

This data says nothing about displaced spending. The Pharmaceutical Journal reported that the Office for Budget Responsibility projects a 25%, or £3.3 billion, rise in branded medicines spending from 2025/26 to 2028/29, while the Health Secretary put the likely figure much lower, at around £1 billion. Health economists quoted there argue the cost falls on other NHS services. Payers will keep that argument in mind when your price is on the table.

What it means for market access teams

  • Do not model the old range as a floor. The ABPI found 54% of appraisals decided at the lower end of the range or below. Expect committees to treat £25,000–£35,000 as a range to be earned with evidence, not a new default.
  • Plan for severity and delay. Disagreement over condition severity arose in 17% of rare-condition appraisals against 3% of common-condition ones, and around one in five appraisals had final guidance delayed by more than a year.
  • Watch the quality-of-life inputs. NICE has said a new value set for valuing health-related quality of life will be used alongside EQ-5D-5L after peer review, and that it may affect cost-effectiveness. Run sensitivity analyses on both.
  • Treat the early numbers as a prompt. Company-reported outcomes from a window with a pause on borderline appraisals will not predict the next 12 months.

To discuss how the new range changes your NICE evidence plan and price positioning, get in touch.